Format

Send to

Choose Destination
J Autoimmun. 2019 Jul;101:121-130. doi: 10.1016/j.jaut.2019.04.012. Epub 2019 Apr 26.

Utilizing a PTPN22 gene signature to predict response to targeted therapies in rheumatoid arthritis.

Author information

1
Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
2
Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States. Electronic address: iho@bwh.harvard.edu.

Abstract

Despite the development of several targeted therapies for rheumatoid arthritis (RA), there is still no reliable drug-specific predictor to assist rheumatologists in selecting the most effective targeted therapy for each patient. Recently, a gene signature caused by impaired induction of PTPN22 in anti-CD3 stimulated peripheral blood mononuclear cells (PBMC) was observed in healthy at-risk individuals. However, the downstream target genes of PTPN22 and the molecular mechanisms regulating its expression are still poorly understood. Here we report that the PTPN22 gene signature is also present in PBMC from patients with active RA and can be reversed after effective treatment. The expression of PTPN22 correlates with that of more than 1000 genes in Th cells of anti-CD3 stimulated PBMC of healthy donors and is inhibited by TNFα or CD28 signals, but not IL-6, through distinct mechanisms. In addition, the impaired induction of PTPN22 in PBMC of patients with active RA can be normalized in vitro by several targeted therapies. More importantly, the in vitro normalization of PTPN22 expression correlates with clinical response to the targeted therapies in a longitudinal RA cohort. Thus, in vitro normalization of PTPN22 expression by targeted therapies can potentially be used to predict clinical response.

KEYWORDS:

CD28; PTPN22; Response prediction; Rheumatoid arthritis; TNFα; Targeted therapy

PMID:
31030958
PMCID:
PMC6556429
[Available on 2020-07-01]
DOI:
10.1016/j.jaut.2019.04.012

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center